With Phase III Success, PharmaEssentia To Seek Besremi Label Expansion (Update)

 
• By Joseph Haas

Taiwan-based PharmaEssentia hopes to add essential thrombocytopenia to the label for its pegylated interferon product, already approved to treat polycythemia vera.

PharmaEssentia wants to add a second platelet disorder to the Besremi label (Shutterstock)

More from Clinical Trials

More from Therapy Areas